Design and evaluation of a supramolecular boron compound using a cyclodextrin-based polyrotaxane for boron neutron capture therapy.

Boron neutron capture therapy (BNCT) has recently attracted attention as a new cancer treatment option. In BNCT, boron compounds need to accumulate efficiently in tumor tissues to achieve excellent therapeutic effects. Therefore, it is highly desirable to develop a technology that can selectively and efficiently deliver boron compounds to tumors.